ABBV-901 / AbbVie - LARVOL DELTA

A phase I first-in-human, open-label study evaluating safety, pharmacokinetics, and efficacy of ABBV-901 as monotherapy and in combination with bevacizumab (Bev) in adult patients with platinum-resistant ovarian cancer (PROC) (ESMO-Gynae 2026) - P1 | "Background The use of the antibody-drug conjugate (ADC) mirvetuximab soravtansine to target folate receptor alpha (FRα) and deliver a cytotoxic maytansine payload is a clinically validated strategy for patients with PROC and high expression levels of FRα. The primary endpoints are the rate of complete/partial response and the frequency and severity of adverse events. Key secondary endpoints include duration of response, progression free survival, and overall survival."

Clinical • Combination therapy • First-in-human • Monotherapy • P1 data • PK/PD data • Platinum resistant • Fallopian Tube Cancer • Gynecologic Cancers • Oncology • Ovarian Cancer • Peritoneal Cancer • Solid Tumor • FOLR1 • PROC